NCT04548219View on ClinicalTrials.gov

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

January 11, 2021

Study Completion Date

January 11, 2021

Conditions
Healthy
Interventions
DRUG

Mirikizumab

Reference and test formulations of mirikizumab administered as a SC injection.

Trial Locations (1)

65802

QPS, Springfield

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04548219 - A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants | Biotech Hunter | Biotech Hunter